Results 91 to 100 of about 44,594 (195)

Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study

open access: yesMalaria Journal, 2018
Background Plasmodium vivax malaria is characterized by relapses arising from the hypnozoite stages in the liver. The only currently registered drug for radical treatment to prevent relapse is primaquine.
Kanokpich Puaprasert   +7 more
doaj   +1 more source

The CYP2D6 VCF Translator [PDF]

open access: yesThe Pharmacogenomics Journal, 2016
W, Qiao   +5 more
openaire   +2 more sources

Variantes alélicas de CYP2D6: *4, *6 y *10 en una muestra de residentes del estado Aragua, Venezuela

open access: yesRevista Peruana de Medicina Experimental y Salud Pública
El objetivo del estudio fue determinar la frecuencia de las variantes del gen CYP2D6: *4, *6 y *10 y predecir el fenotipo metabolizador en una muestra de 145 individuos no consanguíneos, aparentemente sanos, residentes del estado Aragua, Venezuela.
Carlos Flores-Angulo   +5 more
doaj   +2 more sources

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity

open access: yesHuman Genomics
Background Individual assessment of CYP enzyme activities can be challenging. Recently, the potato alkaloid solanidine was suggested as a biomarker for CYP2D6 activity.
Johanna I. Kiiski   +12 more
doaj   +1 more source

Duloksetins betydning for serumkonsentrasjonen av psykofarmaka som omsettes via CYP2D6 [PDF]

open access: yes, 2009
Bakgrunn: Duloksetin er et relativt nytt antidepressivum som hemmer reopptak av serotonin og noradrenalin intersynaptisk. Det metaboliseres via Cytokrom P450 2D6 (CYP2D6) og CYP1A2, men antas også å være en svak/moderat hemmer av CYP2D6.
Enoksen, Torill Bakko
core  

Polymorphic drug metabolising enzymes:Assessment of activities by phenotyping and genotyping in clinical pharmacology [PDF]

open access: yes, 2001
Drug effects (pharmacodynamics) are determined by drug concentration at target site and the affinity of the drug for a target. Pharmacogenetics describes inherited differences in drug metabolising enzyme activities and differences in drug transporters ...
Tamminga, Willem Jan
core   +2 more sources

FROM THE EDITOR

open access: yesФармакокинетика и Фармакодинамика, 2014
В настоящем номере представлен ряд актуальных обзоров, посвящённых изучению новых лекарственных средств и межлекарственному взаимодействию. Прежде всего, продолжается серия обзоров, связанных с исследованием функционирования и полиморфизма известных ...

doaj  

Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen. [PDF]

open access: yes, 2010
Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early and advanced stage breast cancer in women and men. It is a pro-drug having weak affinity with the estrogen receptor and needs to be converted to its main metabolite, endoxifen ...
Berthod, G.   +10 more
core  

Review of existing methodologies to assess the activity of CYP2D6 using exogenous and endogenous markers

open access: yesФармакокинетика и Фармакодинамика, 2014
Peculiarities of functioning and polymorphism of cytochrome P450 isoenzyme CYP2D6. Existing methods for determining its activity using endogenous markers.
A. D. Abdrashitov   +3 more
doaj  

DEVELOPMENT AND VALIDATION OF SIMULTANEOUS ASSAY OF SUBSTRATES-MARKERS OF MAIN CYTOCHROME P450 ISOFORMS AND THEIR METABOLITES USING HPLC-MS/MS

open access: yesРазработка и регистрация лекарственных средств, 2019
Simultaneous quantification method of assaying main CYP isoforms substrates-markers and their metabolites in urine using HPLC-MS/MS was developed to determine activity of following isoforms: caffeine/paraxanthine for CYP1A2, losartane/E-3174 for CYP2C9 ...
E. A. Egorenkov, V. V. Smirnov
doaj  

Home - About - Disclaimer - Privacy